Clinical trials of new antipsychotics: a critical appraisal

被引：7

作者：

Barbui, C ^{[1
]}

Garattini, S ^{[1
]}

机构：

[1] Mario Negri Inst Pharmacol Res, Lab Epidemiol & Social Psychiat, WHO, Collaborating Ctr Res & Training Mental Hlth, I-20157 Milan, Italy

来源：

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 1999年 / 14卷 / 02期

关键词：

antipsychotic drugs; randomized controlled trials; schizophrenia; trial methodology;

D O I：

10.1097/00004850-199903000-00012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonstrating superiority of effect of the new antipsychotic over the reference one. Int Clin Psychopharmacol 14:133-137 (C) 1999 Lippincott Williams & Wilkins.

引用

页码：133 / 137

页数：5

共 27 条

[1] STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE [J].

ALTMAN, DG ;

BLAND, JM .

BRITISH MEDICAL JOURNAL, 1995, 311 (7003) :485-485

[2]

Barbui C, 1998, AM J PSYCHIAT, V155, P152

[3] ZOTEPINE IN THE TREATMENT OF SCHIZOPHRENIC-PATIENTS WITH PREVAILINGLY NEGATIVE SYMPTOMS - A DOUBLE-BLIND TRIAL VS HALOPERIDOL [J].

BARNAS, C ;

STUPPACK, CH ;

MILLER, C ;

HARING, C ;

SPERNERUNTERWEGER, B ;

FLEISCHHACKER, WW .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 7 (01) :23-27

[4] Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].

Beasley, CM ;

Hamilton, SH ;

Crawford, AM ;

Dellva, MA ;

Tollefson, GD ;

Tran, PV ;

Blin, O ;

Beuzen, JN .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137

[5] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].

Beasley, CM ;

Tollefson, G ;

Tran, P ;

Satterlee, W ;

Sanger, T ;

Hamilton, S ;

Fabre, L ;

Small, J ;

Ereshefsky, L ;

True, J ;

Nemeroff, C ;

Risch, SC ;

Perry, PJ ;

Potkin, SG ;

Borison, RL ;

James, S ;

Meltzer, HY ;

Iqbal, N ;

Fann, WE ;

Gewirtz, GR ;

Landbloom, R ;

RoyByrne, PP ;

Tuason, VB ;

Carman, JS ;

Stokes, PE ;

Williams, R ;

Ancill, RJ ;

MacEwan, GW ;

Gujavarty, KS ;

Jones, B ;

Lohr, JB .

NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123

[6] Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study [J].

Bondolfi, G ;

Dufour, H ;

Patris, M ;

May, JP ;

Billeter, U ;

Eap, CB ;

Baumann, P .

AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :499-504

[7]

Bondolfi Guido, 1996, European Neuropsychopharmacology, V6, pS2

[8] THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT [J].

COOK, RJ ;

SACKETT, DL .

BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :452-454

[9]

CUNNINGHAMOWENS DC, 1996, DRUGS, V51, P895

[10] Commentary: The problem of cogent subgroups: A clinicostatistical tragedy [J].

Feinstein, AR .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (04) :297-299

← 1 2 3 →